Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02300870

Enrollment

Registered

2014-11-25

Start date

2015-01-31

Completion date

2019-12-31

Last updated

2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Transplantation

Keywords

Acute rejection, myocardial blood flow

Brief summary

The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term outcomes.

Interventions

DRUGOptison

Echocardiogram with IV contrast

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* All adult subjects (ages 18 to 75) who have undergone heart transplant at Brigham and Women's Hospital

Exclusion criteria

* hemodynamic instability (e.g., systolic blood pressure \< 90 mmHg) * atrial fibrillation with rapid ventricular response (e.g., heart rate \> 120 bpm) * premature atrial or ventricular complexes of a frequency that will not allow adequate echocardiographic assessment * poor acoustic windows * inability to provide informed consent * any contraindication listed in the Optison package insert (i.e., history of an allergic reaction)

Design outcomes

Primary

Measure	Time frame	Description
Global and regional microvascular myocardial perfusion	Baseline	Myocardial blood flow (dB/s)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026